Key Points
- Director Rebecca Robertson sold 827 shares at an average price of $16.67 for a total of $13,786.09 on Dec. 2, reducing her stake by 8.97% to 8,388 shares valued at about $139,828.
- CeriBell shares traded up to $19.64 with a market cap of $728.6M; the company beat recent revenue and EPS estimates for the quarter but remains unprofitable with negative margins, and analysts hold a consensus rating of “Moderate Buy” with a $25.17 target.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca Robertson sold 827 shares of the company's stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $16.67, for a total transaction of $13,786.09. Following the sale, the director directly owned 8,388 shares in the company, valued at $139,827.96. This trade represents a 8.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
CeriBell Price Performance
Shares of CBLL stock traded up $0.49 on Friday, reaching $19.64. The company's stock had a trading volume of 149,288 shares, compared to its average volume of 302,333. The company has a market capitalization of $728.64 million, a P/E ratio of -13.01 and a beta of 1.35. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $32.75. The stock's 50 day simple moving average is $13.27 and its 200-day simple moving average is $14.40. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. The business had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. As a group, equities analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.
Institutional Trading of CeriBell
A number of hedge funds have recently modified their holdings of CBLL. Deutsche Bank AG increased its stake in shares of CeriBell by 0.4% in the 1st quarter. Deutsche Bank AG now owns 231,629 shares of the company's stock worth $4,450,000 after acquiring an additional 842 shares in the last quarter. CenterBook Partners LP bought a new position in CeriBell during the 1st quarter valued at approximately $3,531,000. Swiss National Bank purchased a new position in CeriBell during the first quarter valued at $467,000. Nuveen LLC bought a new stake in CeriBell in the first quarter worth $311,000. Finally, Lord Abbett & CO. LLC grew its stake in shares of CeriBell by 7.9% in the first quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock worth $6,138,000 after acquiring an additional 23,451 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the stock. Raymond James Financial started coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a "strong-buy" rating and a $19.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a report on Wednesday, November 5th. Weiss Ratings restated a "sell (e+)" rating on shares of CeriBell in a research report on Wednesday, October 8th. Finally, TD Cowen decreased their price target on shares of CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $25.17.
Check Out Our Latest Report on CeriBell
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
